Purchases through the above links give commission which helps fund this website
Recent literature: Dipeptidyl peptidase 4 inhibitor
Date Journal Article title
2020 PLoS One Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.
2020 Jan Pharmacol Res Incretins and microRNAs: interactions and physiological relevance.
2020 Jan Biochem Biophys Res Commun The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
2020 Jan Arch Physiol Biochem Protective effect of saxagliptin against renal ischaemia reperfusion injury in rats.
2020 Jan Sci Rep Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
2020 Jan Biochem Biophys Res Commun Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions.
2020 BMJ Open Diabetes Res Care Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene.
2020 BMJ Open Diabetes Res Care Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study.
2020 Jan Diabetes Ther Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database.
2020 Endocrinol Diabetes Metab The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care.
2019 Diabetes Metab Syndr Obes Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus.
2020 Jan Diabetes Res Clin Pract Pharmacological intervention for diabetes after pregnancy prevention in women with prior gestational diabetes: A scoping review.
2020 Jan Prep Biochem Biotechnol A dipyrrole derivative from iAloe verai inhibits an anti-diabetic drug target Dipeptidyl Peptidase (DPP)-IV iin vitroi.
2019 J Obes Metab Syndr Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease.
2020 Jan Thorac Cancer Vildagliptin-induced ground-glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic plementation.
2020 Jan Diabetes Obes Metab Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States.
2019 Pharm Pract (Granada) Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series.
2019 Diabetol Metab Syndr Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study.
2019 J Clin Exp Hepatol Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.
2020 Cancer Epidemiol Anti-diabetic medications and the risk for colorectal cancer: A population-based nested case-control study.
2019 Dec J Dermatol Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
2019 Dec Biology (Basel) The Biological Impacts of Sitagliptin on the Pancreas of a Rat Model of Type 2 Diabetes Mellitus: Drug Interactions with Metformin.
2019 Dec Arch Biochem Biophys Teneligliptin prevents doxorubicin-induced inflammation and apoptosis in H9c2 cells.
2020 J Manag Care Spec Pharm Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
2019 Dec Curr Top Med Chem Integrated Protocol to Design Potential Inhibitors of Dipeptidyl Peptidase-4 (DPP-4).
2019 PLoS Med Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
2019 Dec Adv Ther Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
2019 Dec BMC Cardiovasc Disord Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis.
2019 Dec Diabetes Ther Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.
2019 Dec Gynecol Endocrinol The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review.
2019 Drugs Context Clinical potential of treatment with semaglutide in type 2 diabetes patients.
2020 Jan Life Sci Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes.
2020 Diabetes Ther Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
2020 Diabetes Ther Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study.
2020 Eur J Clin Pharmacol Association between dipeptidyl peptidase-4 inhibitor and aspiration pneumonia: disproportionality analysis using the spontaneous reporting system in Japan.
2020 Trends Endocrinol Metab Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
2019 Dec Eur J Heart Fail European Society of CardiologyHeart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
2020 Mayo Clin Proc Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study.
2020 Neurochem Int The role of linagliptin, a selective dipeptidyl peptidase-4 inhibitor, in the morphine rewarding effects in rats.
2019 Dec Neurosci Bull DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKTmTOR Pathway and Anti-apoptotic Effects.
2020 Diabetologia GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study.
2019 Dec Drug Dev Ind Pharm Formulation and optimization for DPP-4 inhibitor nanomicelles using response surface methodology.
2019 PLoS One A siRNA mediated hepatic dpp4 knockdown affects lipid, but not glucose metabolism in diabetic mice.
2019 Dec Diabetes Obes Metab Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes.
2019 Aging Dis Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
2019 Biol Pharm Bull Characteristics and Early Hypoglycemic Medications of Patients at Risk of Progression to Type 2 Diabetes in Japan: A Retrospective Cohort Study of Health Checkup and Claims Data.
2019 Yakugaku Zasshi [Adherence to Oral Antihyperglycemic Agents (Dipeptidyl Peptidase-4 Inhibitors and Biguanides) and Its Associated Factors in Patients with Type 2 Diabetes].
2019 Nov Chem Biol Interact Effect of resveratrol on dipeptidyl peptidase-4 inhibitors pharmacokinetics: An in vitro and in vivo approach.
2019 J Manag Care Spec Pharm Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes.
2019 Dec Curr Med Res Opin Comparison of persistence and adherence between DPP-4 inhibitor administration frequencies in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.
2019 Nov J Diabetes Investig Potential linkage between dipeptidyl peptidase-4 inhibitor use and the risk of pancreatitispancreatic cancer.
2019 Nov Naunyn Schmiedebergs Arch... Protective effect of dipeptidyl peptidase-4 inhibitors in testicular torsiondetorsion in rats: a possible role of HIF-1α and nitric oxide.
2020 Diabet Med More recent, better designed studies have weakened links between antidiabetes medications and cancer risk.
2019 Liver Cancer Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62 Keap1Nrf2-Pentose Phosphate Pathway in a Mouse Model.
2019 Pharmacol Res Perspect Association between use of oral hypoglycemic agents in Japanese patients with type 2 diabetes mellitus and risk of depression: A retrospective cohort study.
2019 Nov Diabetes Obes Metab Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
2019 Nov Int Heart J Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice.
2020 Hypertension Activation of Transient Receptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction.
2019 Transplant Proc Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus.
2019 Nov Cardiovasc Diabetol Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
2019 Nov Neurotherapeutics Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 ReceptorPI3KAktBDNF Pathway in 3-Nitropropionic Acid Rat Model.
2019 Nov J Health Popul Nutr Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and GLP-1 analog administration in patients with type 2 diabetes mellitus.
2020 Arch Pharm (Weinheim) Benzo[4,5]thieno[2,3-d]pyrimidine phthalimide derivative, one of the rare noncompetitive inhibitors of dipeptidyl peptidase-4.
2019 Oct Diabetes Metab J Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice.
2019 Diabetol Metab Syndr Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database.
2019 Nov J Invest Surg Dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin alleviates lipopolysaccharide-induced acute lung injury via regulating the Nrf-2HO-1 and NF-biκibB pathways.
2019 Nov Diabetes Obes Metab Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes.
2019 Nov Diabet Med Intensive monitoring of adverse drug events associated with the use of new glucose-lowering drugs: results from an inception cohort study in Portugal.
2020 Expert Opin Pharmacother Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
2019 Int J Nanomedicine Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo.
2020 Jan Eur J Med Chem Nitrothiadiazolo[3,2-a]pyrimidines as promising antiglycating agents.
2019 Korean J Physiol Pharmacol Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study.
2019 Dec Toxicol Appl Pharmacol Dipeptidyl peptidase-4 inhibitor sitagliptin induces vasorelaxation via the activation of Kv channels and PKA.
2019 Dec Life Sci Saxagliptin mitigates airway inflammation in a mouse model of acute asthma via modulation of NF-kB and TLR4.
2020 Diabetes Ther Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial.